<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">31021398</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2133</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>182</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>The British journal of dermatology</Title>
          <ISOAbbreviation>Br J Dermatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pathophysiology of pachyonychia congenita-associated palmoplantar keratoderma: new insights into skin epithelial homeostasis and avenues for treatment.</ArticleTitle>
        <Pagination>
          <StartPage>564</StartPage>
          <EndPage>573</EndPage>
          <MedlinePgn>564-573</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/bjd.18033</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Pachyonychia congenita (PC), a rare genodermatosis, primarily affects ectoderm-derived epithelial appendages and typically includes oral leukokeratosis, nail dystrophy and very painful palmoplantar keratoderma (PPK). PC dramatically impacts quality of life although it does not affect lifespan. PC can arise from mutations in any of the wound-repair-associated keratin genes KRT6A, KRT6B, KRT6C, KRT16 or KRT17. There is no cure for this condition, and current treatment options for PC symptoms are limited and palliative in nature.</AbstractText>
          <AbstractText Label="OBJECTIVES">This review focuses on recent progress made towards understanding the pathophysiology of PPK lesions, the most prevalent and debilitating of all PC symptoms.</AbstractText>
          <AbstractText Label="METHODS">We reviewed the relevant literature with a particular focus on the Krt16 null mouse, which spontaneously develops footpad lesions that mimic several aspects of PC-associated PPK.</AbstractText>
          <AbstractText Label="RESULTS">There are three main stages of progression of PPK-like lesions in Krt16 null mice. Ahead of lesion onset, keratinocytes in the palmoplantar (footpad) skin exhibit specific defects in terminal differentiation, including loss of Krt9 expression. At the time of PPK onset, there is elevated oxidative stress and hypoactive Keap1-Nrf2 signalling. During active PPK, there is a profound defect in the ability of the epidermis to maintain or return to normal homeostasis.</AbstractText>
          <AbstractText Label="CONCLUSIONS">The progress made suggests new avenues to explore for the treatment of PC-based PPK and deepens our understanding of the mechanisms controlling skin tissue homeostasis. What's already known about this topic? Pachyonychia congenita (PC) is a rare genodermatosis caused by mutations in KRT6A, KRT6B, KRT6C, KRT16 and KRT17, which are normally expressed in skin appendages and induced following injury. Individuals with PC present with multiple clinical symptoms that usually include thickened and dystrophic nails, palmoplantar keratoderma (PPK), glandular cysts and oral leukokeratosis. The study of PC pathophysiology is made challenging because of its low incidence and high complexity. There is no cure or effective treatment for PC. What does this study add? This text reviews recent progress made when studying the pathophysiology of PPK associated with PC. This recent progress points to new possibilities for devising effective therapeutics that may complement current palliative strategies.</AbstractText>
          <CopyrightInformation>© 2019 British Association of Dermatologists.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zieman</LastName>
            <ForeName>A G</ForeName>
            <Initials>AG</Initials>
            <Identifier Source="ORCID">0000-0001-8236-207X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Cell and Developmental Biology, University of Michigan Medical School, 3071 Biomedical Sciences Research Building, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, U.S.A.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coulombe</LastName>
            <ForeName>P A</ForeName>
            <Initials>PA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell and Developmental Biology, University of Michigan Medical School, 3071 Biomedical Sciences Research Building, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, U.S.A.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, University of Michigan Medical School, 3071 Biomedical Sciences Research Building, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, U.S.A.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AR044232</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 CA009110</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>07</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Br J Dermatol</MedlineTA>
        <NlmUniqueID>0004041</NlmUniqueID>
        <ISSNLinking>0007-0963</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000072019">Kelch-Like ECH-Associated Protein 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053536">Keratin-16</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Br J Dermatol. 2020 Mar;182(3):525-526</RefSource>
          <PMID Version="1">31814103</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072019" MajorTopicYN="N">Kelch-Like ECH-Associated Protein 1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053536" MajorTopicYN="N">Keratin-16</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007645" MajorTopicYN="Y">Keratoderma, Palmoplantar</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053549" MajorTopicYN="Y">Pachyonychia Congenita</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>Conflict of interest disclosures</b>: None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31021398</ArticleId>
        <ArticleId IdType="mid">NIHMS1025908</ArticleId>
        <ArticleId IdType="pmc">PMC6814456</ArticleId>
        <ArticleId IdType="doi">10.1111/bjd.18033</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Leachman SA, Kaspar RL, Fleckman P
et al.
Clinical and pathological features of pachyonychia congenita. The journal of investigative dermatology. Symposium proceedings
2005; 10: 3–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16250204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson NJ, Messenger AG, Leachman SA
et al.
Keratin K6c mutations cause focal palmoplantar keratoderma. The Journal of investigative dermatology
2010; 130: 425–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19609311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McLean WH, Rugg EL, Lunny DP
et al.
Keratin 16 and keratin 17 mutations cause pachyonychia congenita. Nature genetics
1995; 9: 273–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7539673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith FJ, Jonkman MF, van Goor H
et al.
A mutation in human keratin K6b produces a phenocopy of the K17 disorder pachyonychia congenita type 2. Human molecular genetics
1998; 7: 1143–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9618173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bowden PE, Haley JL, Kansky A
et al.
Mutation of a type II keratin gene (K6a) in pachyonychia congenita. Nature genetics
1995; 10: 363–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7545493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franklin J
Pachyonychia Congenita (Jadassohn and Lewandowski). Proceedings of the Royal Society of Medicine
1939; 32: 263–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1997462</ArticleId>
            <ArticleId IdType="pubmed">19991775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson AD, Lawler SD. Pachyonychia congenita; a report of six cases in one family, with a note on linkage data. Annals of eugenics
1951; 16: 142–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14885876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao H, Sayers JM, Wilson NJ
et al.
A spectrum of mutations in keratins K6a, K16 and K17 causing pachyonychia congenita. Journal of dermatological science
2007; 48: 199–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17719747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu T, Leachman SA, Wilson NJ
et al.
Genotype-phenotype correlations among pachyonychia congenita patients with K16 mutations. The Journal of investigative dermatology
2011; 131: 1025–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3775566</ArticleId>
            <ArticleId IdType="pubmed">21160496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin MT, Levy ML, Bowden PE
et al.
Identification of sporadic mutations in the helix initiation motif of keratin 6 in two pachyonychia congenita patients: further evidence for a mutational hot spot. Experimental dermatology
1999; 8: 115–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10232401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krupiczojc MA, O’Toole EA. Plantar pain in pachyonychia congenita. The British journal of dermatology
2018; 179: 11–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30156287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brill S, Sprecher E, Smith FJD
et al.
Chronic pain in pachyonychia congenita: evidence for neuropathic origin. The British journal of dermatology
2018; 179: 154–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29210461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinberg RL, Coulombe, P.A., Polydefkis, M., Caterina, M.J. Pain mechanisms in heriditary Palmoplantar Keratoderma. The British journal of dermatology
2019; In press.</Citation>
        </Reference>
        <Reference>
          <Citation>Coulombe PA, Fuchs E. Epidermolysis bullosa simplex. Seminars in dermatology
1993; 12: 173–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7692916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coulombe PA, Hutton ME, Letai A
et al.
Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients: genetic and functional analyses. Cell
1991; 66: 1301–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1717157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coulombe PA, Hutton ME, Vassar R
et al.
A function for keratins and a common thread among different types of epidermolysis bullosa simplex diseases. The Journal of cell biology
1991; 115: 1661–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2289221</ArticleId>
            <ArticleId IdType="pubmed">1721910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coulombe PA, Kerns ML, Fuchs E. Epidermolysis bullosa simplex: a paradigm for disorders of tissue fragility. J Clin Invest
2009; 119: 1784–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2701872</ArticleId>
            <ArticleId IdType="pubmed">19587453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reis A, Hennies HC, Langbein L
et al.
Keratin 9 gene mutations in epidermolytic palmoplantar keratoderma (EPPK). Nature genetics
1994; 6: 174–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7512862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Langbein L, Heid HW, Moll I
et al.
Molecular characterization of the body site-specific human epidermal cytokeratin 9: cDNA cloning, amino acid sequence, and tissue specificity of gene expression. Differentiation; research in biological diversity
1993; 55: 57–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7507869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim D, Hossain MZ, Nieves A
et al.
To Control Site-Specific Skin Gene Expression, Autocrine Mimics Paracrine Canonical Wnt Signaling and Is Activated Ectopically in Skin Disease. The American journal of pathology
2016; 186: 1140–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4861769</ArticleId>
            <ArticleId IdType="pubmed">27105735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leachman SA, Hickerson RP, Schwartz ME
et al.
First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Molecular therapy : the journal of the American Society of Gene Therapy
2010; 18: 442–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2839285</ArticleId>
            <ArticleId IdType="pubmed">19935778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao YA, Hickerson RP, Seegmiller BL
et al.
Gene expression profiling in pachyonychia congenita skin. Journal of dermatological science
2015; 77: 156–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4374015</ArticleId>
            <ArticleId IdType="pubmed">25656049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldberg I, Fruchter D, Meilick A
et al.
Best treatment practices for pachyonychia congenita. Journal of the European Academy of Dermatology and Venereology : JEADV
2014; 28: 279–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23363249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moll R, Franke WW, Schiller DL
et al.
The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell
1982; 31: 11–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6186379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hesse M, Magin TM, Weber K. Genes for intermediate filament proteins and the draft sequence of the human genome: novel keratin genes and a surprisingly high number of pseudogenes related to keratin genes 8 and 18. Journal of cell science
2001; 114: 2569–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11683385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schweizer J, Bowden PE, Coulombe PA
et al.
New consensus nomenclature for mammalian keratins. The Journal of cell biology
2006; 174: 169–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2064177</ArticleId>
            <ArticleId IdType="pubmed">16831889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyner AL, Fuchs E. Evidence for posttranscriptional regulation of the keratins expressed during hyperproliferation and malignant transformation in human epidermis. The Journal of cell biology
1986; 103: 1945–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2114388</ArticleId>
            <ArticleId IdType="pubmed">2430980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi K, Yan B, Yamanishi K
et al.
The two functional keratin 6 genes of mouse are differentially regulated and evolved independently from their human orthologs. Genomics
1998; 53: 170–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9790766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi K, Paladini RD, Coulombe PA. Cloning and characterization of multiple human genes and cDNAs encoding highly related type II keratin 6 isoforms. The Journal of biological chemistry
1995; 270: 18581–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7543104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenberg M, RayChaudhury A, Shows TB
et al.
A group of type I keratin genes on human chromosome 17: characterization and expression. Molecular and cellular biology
1988; 8: 722–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC363198</ArticleId>
            <ArticleId IdType="pubmed">2451124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernot KM, Coulombe PA, McGowan KM. Keratin 16 expression defines a subset of epithelial cells during skin morphogenesis and the hair cycle. The Journal of investigative dermatology
2002; 119: 1137–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12445204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGowan KM, Coulombe PA. Onset of keratin 17 expression coincides with the definition of major epithelial lineages during skin development. The Journal of cell biology
1998; 143: 469–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2132846</ArticleId>
            <ArticleId IdType="pubmed">9786956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Troyanovsky SM, Leube RE, Franke WW. Characterization of the human gene encoding cytokeratin 17 and its expression pattern. European journal of cell biology
1992; 59: 127–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1281771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Roop DR. Mouse models in preclinical studies for pachyonychia congenita. The journal of investigative dermatology. Symposium proceedings
2005; 10: 37–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16250208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zieman A, Poll BG, Ma J
et al.
Altered keratinocyte differentiation is an early driver of keratin mutation-based palmoplantar keratoderma. Human molecular genetics
2019; In Press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6602407</ArticleId>
            <ArticleId IdType="pubmed">31220272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu DJ, Thomson C, Lunny DP
et al.
Keratin 9 is required for the structural integrity and terminal differentiation of the palmoplantar epidermis. The Journal of investigative dermatology
2014; 134: 754–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3923277</ArticleId>
            <ArticleId IdType="pubmed">23962810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerns ML, Hakim JM, Lu RG
et al.
Oxidative stress and dysfunctional NRF2 underlie pachyonychia congenita phenotypes. J Clin Invest
2016; 126: 2356–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4887188</ArticleId>
            <ArticleId IdType="pubmed">27183391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lessard JC, Coulombe PA. Keratin 16-null mice develop palmoplantar keratoderma, a hallmark feature of pachyonychia congenita and related disorders. The Journal of investigative dermatology
2012; 132: 1384–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3326191</ArticleId>
            <ArticleId IdType="pubmed">22336941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lessard JC, Pina-Paz S, Rotty JD
et al.
Keratin 16 regulates innate immunity in response to epidermal barrier breach. Proc Natl Acad Sci U S A
2013; 110: 19537–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3845144</ArticleId>
            <ArticleId IdType="pubmed">24218583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quigley DA, To MD, Perez-Losada J
et al.
Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature
2009; 458: 505–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4460995</ArticleId>
            <ArticleId IdType="pubmed">19136944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quigley DA, Kandyba E, Huang P
et al.
Gene Expression Architecture of Mouse Dorsal and Tail Skin Reveals Functional Differences in Inflammation and Cancer . Cell reports
2016; 16: 1153–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5087975</ArticleId>
            <ArticleId IdType="pubmed">27425619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Covello SP, Smith FJ, Sillevis Smitt JH
et al.
Keratin 17 mutations cause either steatocystoma multiplex or pachyonychia congenita type 2. The British journal of dermatology
1998; 139: 475–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9767294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith FJ, Corden LD, Rugg EL
et al.
Missense mutations in keratin 17 cause either pachyonychia congenita type 2 or a phenotype resembling steatocystoma multiplex. The Journal of investigative dermatology
1997; 108: 220–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9008238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith FJ, Fisher MP, Healy E
et al.
Novel keratin 16 mutations and protein expression studies in pachyonychia congenita type 1 and focal palmoplantar keratoderma. Experimental dermatology
2000; 9: 170–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10839714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shamsher MK, Navsaria HA, Stevens HP
et al.
Novel mutations in keratin 16 gene underly focal non-epidermolytic palmoplantar keratoderma (NEPPK) in two families. Human molecular genetics
1995; 4: 1875–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8595410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith FJ, Liao H, Cassidy AJ
et al.
The genetic basis of pachyonychia congenita. The journal of investigative dermatology. Symposium proceedings
2005; 10: 21–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16250206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zieman A, Coulombe PA. The keratin 16 null phenotype is modestly impacted by genetic strain background in mice. Experimental dermatology
2018; 27: 672–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6013353</ArticleId>
            <ArticleId IdType="pubmed">29406601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGowan KM, Tong X, Colucci-Guyon E
et al.
Keratin 17 null mice exhibit age- and strain-dependent alopecia. Genes &amp; development
2002; 16: 1412–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC186322</ArticleId>
            <ArticleId IdType="pubmed">12050118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong P, Colucci-Guyon E, Takahashi K
et al.
Introducing a null mutation in the mouse K6alpha and K6beta genes reveals their essential structural role in the oral mucosa. The Journal of cell biology
2000; 150: 921–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2175283</ArticleId>
            <ArticleId IdType="pubmed">10953016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rice RH, Durbin-Johnson BP, Salemi M
et al.
Proteomic profiling of Pachyonychia congenita plantar callus. Journal of proteomics
2017; 165: 132–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5567846</ArticleId>
            <ArticleId IdType="pubmed">28648685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer H, Langbein L, Reichelt J
et al.
Keratins K2 and K10 are essential for the epidermal integrity of plantar skin. Journal of dermatological science
2016; 81: 10–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26603179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tong X, Coulombe PA. Keratin 17 modulates hair follicle cycling in a TNFalpha-dependent fashion . Genes &amp; development
2006; 20: 1353–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1472909</ArticleId>
            <ArticleId IdType="pubmed">16702408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Depianto D, Kerns ML, Dlugosz AA
et al.
Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin. Nature genetics
2010; 42: 910–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2947596</ArticleId>
            <ArticleId IdType="pubmed">20871598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rotty JD, Coulombe PA. A wound-induced keratin inhibits Src activity during keratinocyte migration and tissue repair. The Journal of cell biology
2012; 197: 381–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3341159</ArticleId>
            <ArticleId IdType="pubmed">22529101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung BM, Arutyunov A, Ilagan E
et al.
Regulation of C-X-C chemokine gene expression by keratin 17 and hnRNP K in skin tumor keratinocytes. The Journal of cell biology
2015; 208: 613–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4347647</ArticleId>
            <ArticleId IdType="pubmed">25713416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hobbs RP, DePianto DJ, Jacob JT
et al.
Keratin-dependent regulation of Aire and gene expression in skin tumor keratinocytes. Nature genetics
2015; 47: 933–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4520766</ArticleId>
            <ArticleId IdType="pubmed">26168014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McLean WH, Hansen CD, Eliason MJ
et al.
The phenotypic and molecular genetic features of pachyonychia congenita. The Journal of investigative dermatology
2011; 131: 1015–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21430705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson NJ, Leachman SA, Hansen CD
et al.
A large mutational study in pachyonychia congenita. The Journal of investigative dermatology
2011; 131: 1018–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21326300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eliason MJ, Leachman SA, Feng BJ
et al.
A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. Journal of the American Academy of Dermatology
2012; 67: 680–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22264670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clementi M, Cardin de Stefani E, Dei Rossi C
et al.
Pachyonychia congenita Jackson-Lawler type: a distinct malformation syndrome. The British journal of dermatology
1986; 114: 367–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3954955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feinstein A, Friedman J, Schewach-Millet M. Pachyonychia congenita. Journal of the American Academy of Dermatology
1988; 19: 705–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3053803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munro CS, Carter S, Bryce S
et al.
A gene for pachyonychia congenita is closely linked to the keratin gene cluster on 17q12-q21. Journal of medical genetics
1994; 31: 675–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1050075</ArticleId>
            <ArticleId IdType="pubmed">7529318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terrinoni A, Smith FJ, Didona B
et al.
Novel and recurrent mutations in the genes encoding keratins K6a, K16 and K17 in 13 cases of pachyonychia congenita. The Journal of investigative dermatology
2001; 117: 1391–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11886499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duverger O, Carlson JC, Karacz CM
et al.
Genetic variants in pachyonychia congenita-associated keratins increase susceptibility to tooth decay. PLoS genetics
2018; 14: e1007168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5794186</ArticleId>
            <ArticleId IdType="pubmed">29357356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porter RM, Bravo AA, Smith FJD. Management of Plantar KeratodermasLessons from Pachyonychia Congenita. Journal of the American Podiatric Medical Association
2017; 107: 428–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29077501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leachman SA, Hickerson RP, Hull PR
et al.
Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. Journal of dermatological science
2008; 51: 151–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2587483</ArticleId>
            <ArticleId IdType="pubmed">18495438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hickerson RP, Smith FJ, Reeves RE
et al.
Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. The Journal of investigative dermatology
2008; 128: 594–605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17914454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hickerson RP, Flores MA, Leake D
et al.
Use of self-delivery siRNAs to inhibit gene expression in an organotypic pachyonychia congenita model. The Journal of investigative dermatology
2011; 131: 1037–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21248764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaspar RL, Leachman SA, McLean WH
et al.
Toward a treatment for pachyonychia congenita: report on the 7th Annual International Pachyonychia Congenita Consortium meeting. The Journal of investigative dermatology
2011; 131: 1011–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21494242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hickerson RP, Leake D, Pho LN
et al.
Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. Journal of dermatological science
2009; 56: 82–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19699613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teng JMC, Bartholomew FB, Patel V
et al.
Novel treatment of painful plantar keratoderma in pachyonychia congenita using topical sirolimus. Clinical and experimental dermatology
2018; 43: 968–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29882237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gruber R, Edlinger M, Kaspar RL
et al.
An appraisal of oral retinoids in the treatment of pachyonychia congenita. Journal of the American Academy of Dermatology
2012; 66: e193–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21601946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Gartner U, Smith FJ
et al.
Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita. The Journal of investigative dermatology
2011; 131: 1045–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21390048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdollahimajd F, Rajabi F, Shahidi-Dadras M
et al.
Pachyonychia congenita: a case report of a successful treatment with rosuvastatin in a patient with a KRT6A mutation. The British journal of dermatology
2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30307612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swartling C, Karlqvist M, Hymnelius K
et al.
Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita. The British journal of dermatology
2010; 163: 1072–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20618323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu C
Modification of Keap1 Cysteine Residues by Sulforaphane. 2011; 24: 515–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3086360</ArticleId>
            <ArticleId IdType="pubmed">21391649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerns ML, Hakim JMC, Zieman A
et al.
Sexual Dimorphism in Response to an NRF2 Inducer in a Model for Pachyonychia Congenita. The Journal of investigative dermatology
2018; 138: 1094–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5912985</ArticleId>
            <ArticleId IdType="pubmed">29277538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Talalay P, Cho CG
et al.
A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci U S A
1992; 89: 2399–403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC48665</ArticleId>
            <ArticleId IdType="pubmed">1549603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerns ML, DePianto D, Dinkova-Kostova AT
et al.
Reprogramming of keratin biosynthesis by sulforaphane restores skin integrity in epidermolysis bullosa simplex. Proc Natl Acad Sci U S A
2007; 104: 14460–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1964870</ArticleId>
            <ArticleId IdType="pubmed">17724334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerns ML, Guss L, Fahey J
et al.
Randomized, split-body, single-blinded clinical trial of topical broccoli sprout extract: Assessing the feasibility of its use in keratin-based disorders. Journal of the American Academy of Dermatology
2017; 76: 449–53.e1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5509965</ArticleId>
            <ArticleId IdType="pubmed">27889290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leube RE, Schwarz N. Sex Matters: Interfering with the Oxidative Stress Response in Pachyonychia Congenita. The Journal of investigative dermatology
2018; 138: 1019–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29681388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi K, Coulombe PA. A transgenic mouse model with an inducible skin blistering disease phenotype. Proc Natl Acad Sci U S A
1996; 93: 14776–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC26212</ArticleId>
            <ArticleId IdType="pubmed">8962131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wojcik SM, Imakado S, Seki T
et al.
Expression of MK6a dominant-negative and C-terminal mutant transgenes in mice has distinct phenotypic consequences in the epidermis and hair follicle. Differentiation; research in biological diversity
1999; 65: 97–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10550543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wojcik SM, Longley MA, Roop DR. Discovery of a novel murine keratin 6 (K6) isoform explains the absence of hair and nail defects in mice deficient for K6a and K6b. The Journal of cell biology
2001; 154: 619–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2196416</ArticleId>
            <ArticleId IdType="pubmed">11489919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wojcik SM, Bundman DS, Roop DR. Delayed wound healing in keratin 6a knockout mice. Molecular and cellular biology
2000; 20: 5248–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC85973</ArticleId>
            <ArticleId IdType="pubmed">10866680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong P, Domergue R, Coulombe PA. Overcoming functional redundancy to elicit pachyonychia congenita-like nail lesions in transgenic mice. Molecular and cellular biology
2005; 25: 197–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC538767</ArticleId>
            <ArticleId IdType="pubmed">15601842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Jaeger K, Den Z
et al.
Mice expressing a mutant Krt75 (K6hf) allele develop hair and nail defects resembling pachyonychia congenita. The Journal of investigative dermatology
2008; 128: 270–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17851587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia M, Larcher F, Hickerson RP
et al.
Development of skin-humanized mouse models of pachyonychia congenita. The Journal of investigative dermatology
2011; 131: 1053–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21150925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimonis V, DiGiovanna JJ, Yang JM
et al.
A mutation in the V1 end domain of keratin 1 in non-epidermolytic palmar-plantar keratoderma. The Journal of investigative dermatology
1994; 103: 764–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7528239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arin MJ, Longley MA, Kuster W
et al.
An asparagine to threonine substitution in the 1A domain of keratin 1: a novel mutation that causes epidermolytic hyperkeratosis. Experimental dermatology
1999; 8: 124–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10232403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lugassy J, Itin P, Ishida-Yamamoto A
et al.
Naegeli-Franceschetti-Jadassohn syndrome and dermatopathia pigmentosa reticularis: two allelic ectodermal dysplasias caused by dominant mutations in KRT14. American journal of human genetics
2006; 79: 724–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1592572</ArticleId>
            <ArticleId IdType="pubmed">16960809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armstrong DK, McKenna KE, Purkis PE
et al.
Haploinsufficiency of desmoplakin causes a striate subtype of palmoplantar keratoderma. Human molecular genetics
1999; 8: 143–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9887343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rickman L, Simrak D, Stevens HP
et al.
N-terminal deletion in a desmosomal cadherin causes the autosomal dominant skin disease striate palmoplantar keratoderma. Human molecular genetics
1999; 8: 971–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10332028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGrath JA, McMillan JR, Shemanko CS
et al.
Mutations in the plakophilin 1 gene result in ectodermal dysplasia/skin fragility syndrome. Nature genetics
1997; 17: 240–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9326952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whittock NV, Smith FJ, Wan H
et al.
Frameshift mutation in the V2 domain of human keratin 1 results in striate palmoplantar keratoderma. The Journal of investigative dermatology
2002; 118: 838–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11982762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKoy G, Protonotarios N, Crosby A
et al.
Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet (London, England)
2000; 355: 2119–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10902626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubo A, Shiohama A, Sasaki T
et al.
Mutations in SERPINB7, encoding a member of the serine protease inhibitor superfamily, cause Nagashima-type palmoplantar keratosis. American journal of human genetics
2013; 93: 945–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3824127</ArticleId>
            <ArticleId IdType="pubmed">24207119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maestrini E, Monaco AP, McGrath JA
et al.
A molecular defect in loricrin, the major component of the cornified cell envelope, underlies Vohwinkel’s syndrome . Nature genetics
1996; 13: 70–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8673107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Z, Chen Q, Lee M
et al.
Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome. American journal of human genetics
2012; 90: 558–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3309189</ArticleId>
            <ArticleId IdType="pubmed">22405088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lind L, Lundstrom A, Hofer PA
et al.
The gene for diffuse palmoplantar keratoderma of the type found in northern Sweden is localized to chromosome 12q11-q13. Human molecular genetics
1994; 3: 1789–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7531539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blaydon DC, Lind LK, Plagnol V
et al.
Mutations in AQP5, encoding a water-channel protein, cause autosomal-dominant diffuse nonepidermolytic palmoplantar keratoderma. American journal of human genetics
2013; 93: 330–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3738836</ArticleId>
            <ArticleId IdType="pubmed">23830519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richard G, White TW, Smith LE
et al.
Functional defects of Cx26 resulting from a heterozygous missense mutation in a family with dominant deaf-mutism and palmoplantar keratoderma. Human genetics
1998; 103: 393–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9856479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Steensel MA, Spruijt L, van der Burgt I
et al.
A 2-bp deletion in the GJA1 gene is associated with oculo-dento-digital dysplasia with palmoplantar keratoderma. American journal of medical genetics. Part A
2005; 132a: 171–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15551259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong XQ, Shao Q, Lounsbury CS
et al.
Functional characterization of a GJA1 frameshift mutation causing oculodentodigital dysplasia and palmoplantar keratoderma. The Journal of biological chemistry
2006; 281: 31801–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16891658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giehl KA, Eckstein GN, Pasternack SM
et al.
Nonsense mutations in AAGAB cause punctate palmoplantar keratoderma type Buschke-Fischer-Brauer. American journal of human genetics
2012; 91: 754–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3484507</ArticleId>
            <ArticleId IdType="pubmed">23000146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer J, Bouadjar B, Heilig R
et al.
Mutations in the gene encoding SLURP-1 in Mal de Meleda. Human molecular genetics
2001; 10: 875–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11285253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanderhooft SL, Francis JS, Holbrook KA
et al.
Familial pityriasis rubra pilaris. Archives of dermatology
1995; 131: 448–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7726588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagy N, Wedgeworth E, Hamada T
et al.
Schopf-Schulz-Passarge syndrome resulting from a homozygous nonsense mutation in WNT10A. Journal of dermatological science
2010; 58: 220–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20418069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adaimy L, Chouery E, Megarbane H
et al.
Mutation in WNT10A is associated with an autosomal recessive ectodermal dysplasia: the odonto-onycho-dermal dysplasia. American journal of human genetics
2007; 81: 821–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1973944</ArticleId>
            <ArticleId IdType="pubmed">17847007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blaydon DC, Etheridge SL, Risk JM
et al.
RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. American journal of human genetics
2012; 90: 340–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3276661</ArticleId>
            <ArticleId IdType="pubmed">22265016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toomes C, James J, Wood AJ
et al.
Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis. Nature genetics
1999; 23: 421–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10581027</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
